 Home > Medical News > Medical Research Articles > New therapy is expected to treat lung cancer patients with rare EGFR mutations

New therapy is expected to treat lung cancer patients with rare EGFR mutations

 Last Update: 2021-08-15
 Source: Internet
 Author: User

Tags

science 21

small box freezer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CHRYSALIS is a phase 1, open label, dose escalation and dose expansion trial that evaluates amivantamab, a bispecific antibody with immune cell targeting activity, designed to participate in two different driving pathways of non-small cell lung cancer: EGFR and MET

Epidermal growth factor receptor (EGFR) gene mutations are the most common targeted genomic driver of non-small cell lung cancer

"We have successfully developed targeted therapies for other types of EGFR mutations, but these therapies are less beneficial to patients with EGFR Ex20Ins mutations

Accurate detection of EGFR Ex20Ins mutations is essential to identify lung cancer patients who are most likely to respond to EGFR Ex20Ins targeted therapy

The new expanded data from the CHRYSALIS study included 81 patients

Howrah said: "The results of this study are encouraging because we have seen long-lasting responses in patients with non-small cell lung cancer, a difficult-to-treat subtype

The study of amivantamab in Moffitt's EGFR-mutated and MET-mutated lung cancer patients is still continuing, and the application of the drug in other cancer types is also being explored

A study by Janssen R & D Co.

Journal Reference :

Keunchil Park, Eric B.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Neopentyl Glycol CAS NO.126-30-7 99% High Quality Factory Supply

CAS No.: 126-30-7

Industrial Grade

$1.7-2/KG FOB

Factory Supply Tirzepatide 10 mg 15mg Weight Loss Peptide 10mg 99.9% CAS: 2023788-19-2

CAS No.: 2023788-19-2

Pharmacy Grade

$4-5/UNIT FOB

good quality 2cb wholesale

CAS No.: 58743-75-2

$2-2.2/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.